CV-301: Pilot trial data

Data from a pilot trial in 12 patients with breast cancer showed that monthly CV-301 produced a median TTP and OS of 2.5 and 13.7 months, respectively. One patient had a complete response and 4 patients had stable disease. In 14 patients with ovarian cancer, median TTP and OS were 2 and 15 months, respectively. CV-301 was well tolerated with mild injection-site reactions reported as the most common adverse event. Data were published in Clinical Cancer Research. The National Cancer Institute (NCI) funded the trial. ...